Vera started at buy by Goldman Sachs, atacicept potential cited
Goldman Sachs has initiated coverage of Vera Therapeutics (VERA) with a buy rating, citing its drug candidate atacicept and a ...
ETF Daily News21d
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down Following Insider Selling
Read Our Latest Analysis on VERA Vera Therapeutics Stock Down 0.5 % The company has a market capitalization of $2.19 billion, a P/E ratio of -13.25 and a beta of 1.15. The company has a debt-to ...
Benzinga.com22d
What's Going On With Vera Therapeutics Stock?
Vera Therapeutics shares are trading lower by 7.3% Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109. Get Wall Street's Hottest Chart Every ...
Vera Therapeutics: Promising Clinical Progress and Strategic Positioning Drive Buy Rating
Analyst Farzin Haque of Jefferies maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $58.00.Invest ...
Brokerages Set Vera Therapeutics, Inc. (NASDAQ:VERA) Price Target at $63.50
Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have received a consensus recommendation of “Buy” from the nine brokerages that are presently covering the firm, Marketbeat reports.
Nasdaq28d
Vera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on treatments for serious immunological diseases, announced that its management will present at the 43rd Annual J.P ...
Yahoo Finance22d
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted ...